- Login
- Register & Subscribe
- Language: EN FR DE
Friday 30 July 2010
NicOx SA will be seeking a meeting with the Food and Drug Administration to discuss the agency’s refusal to approve its lead product, naproxcinod, for marketing, the company’s chief executive, Michele Garufi, told analysts in a conference call on 30 July.
Country: France
Friday 30 July 2010
The management of Wilex AG is asking shareholders not to accept an offer for the company from dievini Hopp BioTech holding GmbH. The venture capital firm was obliged to make the offer after its stake in Wilex moved above 30%.
Country: Germany
Thursday 29 July 2010
Sanofi-Aventis managed to offset the impact of generic competition for some of its major products in the quarter and half year ended June 2010. However, it changed its guidance for profit per share at constant exchange rates.
Country: France
Thursday 29 July 2010
For the second time this year, AstraZeneca Plc has raised its guidance for earnings per share in 2010 even as it anticipates a slight decline in revenue and downward pressure on prices in Europe from healthcare reforms. The Anglo-Swedish multinational also said that it is raising its target for the repurchase of its shares on the market to $2 billion, up from $1 billion, and will be paying an interim dividend of $0.70 per share.
Country: United Kingdom
Wednesday 28 July 2010
Addex Pharmaceuticals Ltd said it is prepared to take a more opportunistic approach to out-licensing its allosteric modulator compounds- even if this means opening discussions with potential licensors for very early-stage programmes.
Country: Switzerland
Wednesday 28 July 2010
The antibody business of MorphoSys AG generated a substantial increase in sales and profits for the quarter and half year ended June 2010, giving it an unusual problem of how best to deploy its large cash holdings.
Country: Germany
Wednesday 28 July 2010
Merck Serono said that its new small molecule drug for relapsing-remitting multiple sclerosis, which is an oral formulation of cladribine, has been granted priority review by the FDA, which means a decision can be expected in about six months.
Country: Switzerland
Wednesday 28 July 2010
A cannabis medicine developed by GW Pharmaceuticals Plc for the treatment of spasticity due to multiple sclerosis has been approved by the Spanish regulator. This follows its approval in June, 2010, by the UK regulator, the MHRA.
Country: United Kingdom
Tuesday 27 July 2010
The European Medicines Agency’s main scientific committee has recommended that Boehringer Ingelheim’s new combination pill for hypertension, Twynsta, be approved for marketing.
Country: United Kingdom
Tuesday 27 July 2010
At a time of intense competition in the antibody field, venture capital-backed NovImmune SA of Switzerland has secured an exclusive licensing deal with Genentech Inc for a pre-clinical compound targeting two forms of the Interleukin-17 (IL-17) family of cytokines.
Country: Switzerland
Tuesday September 7 2010
Friday September 3 2010
Friday August 20 2010
Friday August 20 2010
Thursday August 19 2010